Progression into G 1 in B lymphocytes is regulated by cyclins D2 and D3, components of the cell cycle machinery currently believed to have overlapping and potentially redundant roles in cell cycle control. To study the specific role of cyclin D2 in B lymphocyte proliferation, we examined B cells from cyclin D2 -/-mice and demonstrate a specific requirement for cyclin D2 in BCR-but not CD40-or lipopolysaccharide-induced proliferation. Furthermore, conventional B cell development proceeds normally in the mutant mice; however, the CD5 B cell compartment is dramatically reduced, suggesting that cyclin D2 is important in CD5 B cell development as well as antigendependent B cell clonal expansion.
Introduction
The commitment to enter S phase and divide or remain in the types. Results from mice homologous for genetic disruptions in cyclins D1 or D2 suggest that D cyclin function is overlap-G 1 phase with an unduplicated genome takes place in midto-late G 1 and is referred to as the restriction point (R) (1-3).
ping and potentially redundant since viable offspring were obtained in each case (5,6). More direct evidence for overlapOperationally, the restriction point separates the cell cycle into an initial mitogen-dependent period followed by a growth ping roles of D cyclins in proliferation is the ability of cyclins D1, D2 or D3 to restore a normal cycle progression time to a factor-independent stage (1-3). The D-type cyclins are the first components of the cell cycle machinery to become cyclin D1-deficient subline of DT40 (7). However, there are specific lines of evidence in certain cell types suggesting that induced in response to mitogen stimulation (1-3), and their associated kinase activity has a critical role in the commitment an individual D-type cyclin has distinct biological roles during certain cell cycles (8,9) and that D-type cyclins may have to enter S phase by phosphorylating and thereby inactivating pRb, a negative regulator of cell cycle progression (3).
specific roles in cellular processes other than proliferation (10-13). Consistent with their major role in the positive regulation of G 1 , the D-type cyclins are required for S phase entry, and Our laboratory has demonstrated that proliferating B lymphocytes express both cyclin D2 and D3 but not D1 (14); their overexpression both accelerates G 1 and reduces the dependence on exogenous growth factors (4).
however, it is the accumulation of cyclin D2 which has been suggested to be the critical event in passage through the The three D-type cyclins, D1, D2 and D3, are expressed in proliferating cells in a lineage-specific manner with at least restriction point (15). Consistent with this idea, stimulation of B cells with complete versus partial activation signals sugtwo different D-type cyclins being expressed in most cell gests that signals responsible for moving B cells through the restriction point impact at the level of cyclin D2 protein accumulation (14,16).
Further evidence suggesting discrete roles for D-type cyclins in B cells comes from studies of cyclin expression in B leukemia and lymphomas representative of different B cell subsets. Examination of human B cell-derived lines revealed specific phenotype-related differences in D-type cyclin expression (17,18). Furthermore, centrocytic lymphoma, representative of mantle zone B cells, is characterized by a t(11:14) translocation which results in the constitutive expression of cyclin D1, a cyclin which is not normally detected in proliferating mouse or human B cells (19, 20) . In contrast, cyclin D2 but not D1 or D3 was overexpressed in chronic lymphocytic leukemia (CLL), which is thought to be the transformed counterpart of the normal CD5-expressing B cells (21, 22) . These results are consistent with the idea that there may be specific roles for individual D-type cyclins during different B cell developmental stages in addition to specific roles in proliferation.
To sort out the individual role of cyclin D2 in B lymphoid cells we utilized an experimental system which differentially regulates D cyclin induction during G 1 and S phase entry. The model system consists of stimulating normal resting B cells with a low dose of anti-Ig to mimic weak BCR cross- ment for cyclin D2 during S phase entry was confirmed by analysis of B cells from mice homologous for a genetic deletion of cyclin D2. Indeed, cyclin D2 -/-B cells failed to proliferate in response to IL-4 plus low-dose anti-Ig. Additionally, analysis of B cell development in the mutant mice peroxidase (HRP)-conjugated reagents were purchased from revealed a specific diminution in the CD5 B cell compartment Amersham (Arlington Heights, IL). Fluorescent-conjugated while conventional B cell development appeared normal.
antibodies to IgM, B220, IgD, CD5, CD21, CD19 and CD23 These results demonstrate unique and non-redundant roles were purchased from PharMingen (San Diego, CA). HRPfor cyclin D2 during proliferation and development in normal conjugated anti-rat, anti-rabbit and anti-mouse secondary mouse B lymphoid cells. reagents were purchased from Amersham. The affinity-purified F(abЈ) 2 goat anti-mouse IgM used to stimulated B cells Methods was purchased from Cappel (Durham, NC). The rat anti-mouse monoclonal anti-CD40 antibody was described previously. Mice BALB/c mice (6-8 weeks old) were obtained from Simonsen FACS analysis of CD5 B cell population and were used as a source of B cells for initial stimulation
The criteria for identifying CD5-expressing B cells was as with IL-4, low-dose anti-Ig and IL-4 plus low-dose anti-Ig (Fig. follows. CD5 B cells were identified in the normal control 1). The derivation of the cyclin D2 -/-mice and the screening littermates by first staining with the combination of anti-IgMprotocol for heterozygous identification have been previously FITC plus a phycoerythrin (PE)-conjugated isotype control. A described (5). Cyclin D2 mutation is carried on a mixed second aliquot of cells was stained with anti-IgM-FITC plus background of 129S/v and C57BL6. Mice used in experiments anti-CD5-PE. The isotype control profile was used to set the described here were fourth generation. Control mice used horizontal bar for the calculation of the percentage of CD5-for all experiments (except Fig. 1) were the heterozygote expressing cells in the second aliquot of cells. Peritoneal littermate controls.
cells from the mutant mice were stained using the same Reagents combination of antibodies and the settings for CD5 positivity were again obtained from the results from the isotype control Antibodies against cyclins D2, D3 and ERK2 were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). Horseradish antibody.
Purification of splenic B cells Purification of peritoneal CD5 B cells and conventional splenic B cells
To isolate splenic B cells, single-cell suspension were pre-CD5 B cells were purified from the peritoneal cavity of pared from spleens of unprimed mice. Red blood cells were heterozygous littermate control (ϩ/-) mice by sorting with lysed using red blood cell lysis buffer (Sigma, Irvine, CA) monomeric F(abЈ) anti-IgM (Southern Biotechnology Associaccording to the manufacturer's instructions. To deplete ates, Birmingham, AL) in combination with anti-Mac1. The T cells, splenocytes were stained using anti-Thy-1 (NEN sorted peritoneal cell population expressed IgM hi Mac1 lo Research Products, Wilmington, DE) and anti-CD4 (RL172), which are hallmarks characteristics of the CD5 B cell populafollowed by incubation in rabbit complement (Cedarlane, tion. In parallel, total splenic B cells were purified by the Hornby, Ontario, Canada) at 37°C for 45 min. These cells same method and the IgM ϩ Mac1 -cells were collected for were consistently Ͼ90% B220 ϩ IgM ϩ , and included both the comparison. To ensure that the monomeric anti-Ig could not low-and high-density B cells. Mice referred to as wild-type induce cross-linking and subsequent activation of peritoneal in the text are the heterozygous littermate control mice (-/ϩ).
B lymphoid cells during the sorting procedure, the monomeric preparation of anti-IgM was tested for its ability to induce In vitro stimulations and whole-cell lysate preparation splenic B cell proliferation in vitro, a property which is known The expression of cell cycle regulatory proteins in stimulated to require cross-linking of the BCR. The F(abЈ) anti-IgM did B cell populations was evaluated using procedures described not induce splenic B cell proliferation (not shown) nor did it previously (23) . Briefly, 50 ml cultures were set up at 10 6 B stimulate the up-regulation of either cyclin D2 or D3 induction cells/ml in 75 cm 2 flasks (Becton Dickinson, Lincoln Park, NJ) in splenic B cells (see Fig. 5 ), confirming that there was no and stimulated with 100 U/ml IL-4, 1 µg/ml F(abЈ) 2 anti-IgM signal to cell cycle machinery generated at the BCR by the (low-dose anti-Ig) or IL-4 plus 1 µg/ml F(abЈ) 2 anti-IgM (lowsorting reagent. dose anti-Ig). Cells were collected at times indicated poststimulation. All stimulations were carried out in supplemented Results RPMI containing 10% FCS (JR Scientific, Woodland, CA), 5ϫ10 -5 M 2-mercaptoethanol (Polysciences, Warrington, PA), Up-regulation of cyclin D2 in splenic B cells after activation 2 mM glutamate (JR Scientific), 10 mM HEPES buffer (Irvine with IL-4 and low-dose anti-Ig Scientific, Santa Ana, CA), 100 U/ml penicillin and 100 µg/ml
To study the induction of D cyclins during cell cycle progresstreptomycin (Irvine Scientific). Following stimulation, cells sion in B lymphocytes, we stimulated resting splenic B cells were recovered, washed 3 times in cold PBS, divided into with either IL-4 alone, weak BCR cross-linking (mimicked by three pellets, and stored at -80°C for later use in Western a low dose of anti-Ig, 1 µg/ml) alone or the mitogenic blotting and in vitro kinase assays. When all time points were combination of IL-4 plus low-dose anti-Ig. Time points were collected, one pellet from each time point was lysed in NPcollected at 0, 6, 12, 24, 36 and 48 h post-stimulation. Lysates 40 lysis buffer (1% NP-40, 250 mM NaCl, 1 mM HEPES, pH were prepared and 100 µg of total protein from each time 7.5 and 1 mM DTT; USB, Cleveland, OH) with protease point was loaded on a gel. Western blotting was performed inhibitors added [final concentration: 5 µg/ml aprotinin as described previously (23) and the blots were sequentially (Sigma), 125 µg/ml Pefabloc (Boehringer Mannheim, Minneascreened with mAb to cyclin D2, D3 and D1. Results shown polis, MN) and 5 µg/ml pepstatin (Sigma)]. Protein concentrain Fig. 1(a, top) demonstrate that IL-4 stimulation resulted in tions were calculated using a BioRad protein assay kit a dramatic induction of cyclin D2 6 h after stimulation but (BioRad, Hercules, CA) according to the manufacturer's prorapidly diminished thereafter. Cyclin D2 was induced at very cedures. An equal volume of 2ϫSDS sample buffer (Novex, low levels in response to low-dose anti-Ig stimulation and this San Diego, CA) with 2-mercaptoethanol was added to the level of induction was maintained throughout the time course total cell lysates. Then 125 µg of lysate was run per time point (Fig. 1a, middle) . In contrast, stimulation of B cells with the on 12% Novex reducing gels according to the manufacturer's mitogenic combination of IL-4 plus low-dose anti-Ig resulted suggested protocol and transferred onto Immobilon PVDF in the dramatic and sustained induction of cyclin D2 (Fig. 1a , membranes (Millipore, Bedford, MA) at 30 V overnight in 4°C. bottom). Cyclin D3 induction was similar between the three stimuli (Fig. 1b) . To confirm that an equal amount of protein Thymidine incorporation was loaded onto each well, the blots were probed with an antibody to ERK2 which is constitutively expressed under Since the difference in D cyclin induction between all three termate control mice. ELISA was used to quantitate the levels stimulants was primarily at the level of cyclin D2, we examined of individual isotypes levels in the mice according to protocols B cell development and activation in cyclin D2 -/-mice (5). B cells from the heterozygous littermate control (ϩ/-) mice described elsewhere (24). proliferated in response to low-dose anti-Ig plus IL-4 which ( Fig. 2d) and furthermore that the induction of cyclin D3 was similar between the mutant wild-type B cells (not shown). peaked at 48 h post-stimulation (Fig. 2a, squares) . However, B cells from the mutant mice did not proliferate (Fig. 2a ,
Cyclin D2 -/-B cells respond normally to lipopolysaccharide circles). Interestingly, stimulation of mutant B cells through
(LPS) and antibody to CD40 the BCR did not result in an increase in cell death, but rather a specific failure to enter the cell cycle (data not shown). To
We next tested non-BCR mitogens and demonstrated that the study the proliferation defect further, we purified B cells from mutant B cell proliferative response to LPS (Fig. 2e) , a nonthe mutant and wild-type mice, and stimulated them in vitro specific polyclonal B cell mitogen, was only minimally affected with different anti-Ig reagents and monitored the entry into S by the loss of cyclin D2. Similarly, the proliferative response phase with [ 3 H]thymidine incorporation. A dramatic unrein the mutant B cells following stimulation through CD40, a sponsiveness was demonstrated using agonistic mAb dirsignal known to induce long-term proliferation in B lymphocytes in vitro, was intact, although diminished by 35% (Fig. 2e) . ected against IgM (B7-6) (26) or IgD to cross-link the BCR. Using these reagents, the mutant B cell proliferative response Cyclin D2 -/-mice have decreased serum IgG3 and IgA was depressed by 90 and 80% respectively when compared to wild-type B cells (Fig. 2b) . When mutant B cells were Since B lymphocytes with mutations in cyclin D2 exhibit stimulated across a broad range of concentrations of polydefects in proliferation in vitro, we analyzed the serum from clonal anti-Ig, we detected a proliferative response which the mutant mice to determine if there was evidence of approached 30% of the wild-type response at high concentrafunctional defects in the peripheral B cell pool. Serum was tions of anti-Ig (Fig. 2c) . We performed Western blots on B collected from six mutant (Fig. 3, closed circles) and six cells stimulated with a high dose of anti-Ig and confirm that heterozygous littermate control (Fig. 3 , open boxes) mice and compared by ELISA to determine the level of each Ig isotype the proliferation occurred in the absence of cyclin D2 induction IgG3 (P ϭ 0.016) and a less dramatic decrease in the levels in Table 1. of IgA (P ϭ 0.066).
Cyclin D2 -/-mice have reduced CD5 ϩ B cell compartment 1). The failure of the CD5 B cell subset to develop while the Although there have been no previously reported immune conventional B cell compartment is unaffected by the loss of deficiencies in the cyclin D2 -/-mice (5), we were interested cyclin D2 highlights a specific requirement for cyclin D2 to determine if B cell development was affected by a loss of during the genesis of this specific B cell subset. cyclin D2. Since the CD5 B cell population is known to be a To further evaluate the unique requirement for cyclin D2 in major source of both IgG3 and IgA and we detected substandevelopment of CD5-expressing B cells but not conventional tial deficits in these serum isotypes, we examined the mutant B cells, we isolated CD5 B cells from the peritoneal cavity mice to determine if this B cell subset was present. Examinaand conventional B cells from spleen of wild-type mice. tion of the lymphoid compartment in the peritoneal cavity Western blots were prepared from lysates of unstimulated CD5 B cells, CD5 B cells stimulated with IL-4 plus low-dose revealed a dramatic reduction in CD5 B cells in the mutant anti-Ig or unstimulated total splenic B cells (Fig. 5) . Cyclin D2 mice. Figure 4 shows FACS profiles of heterozygote littermate was expressed at high levels in the unstimulated CD5 B cell (ϩ/-) and mutant (-/-) peritoneal cells stained with a panel population and, interestingly, the level of cyclin D2 expression of mAb which identify the CD5 B cell population. In Fig. 4(a) , did not increase following anti-Ig plus IL-4 stimulation in the CD5-expressing B cells are evident in the wild-type (top, this B cell subset. Cyclin D2 was weakly detectable in the see box), but severely diminished in the mutant mouse unstimulated total splenic B cells. The analysis of cyclin D3 (bottom, box). In Fig. 4(b) , the characteristic IgM hi IgD lo popurevealed that the slower migrating D3 form is detected in lation which contains the CD5 B cell subset is again present both activated and non-activated CD5 B cell populations in wild-type but diminished in the mutant mouse. Indeed, our while both forms of D3 are detectable in the total splenic analysis revealed a statistically significant decrease in both B cell population. Neither the functional significance nor the proportion (P ϭ 0.002) and total number (P ϭ 0.005) of biochemical modifications associated with the different CD5-expressing B cells detected in the mutant mice (Table 1) .
migrating forms of cyclin D3 are known. Taken together these Interestingly, we noted that the conventional B cell compartresults confirm a differential expression of cyclin D2 and D3 ment (IgM lo IgD hi ) was intact in the peritoneal cavity of both in the normal peritoneal CD5 population. The unexpected the wild-type and mutant mouse (Fig. 4b, arrow) suggesting expression of high levels of the G 1 -promoting cyclin, D2, in that B cell development in the bone marrow was not affected resting CD5 B cells is consistent with the suggestion that by loss of cyclin D2. Indeed, we detected no significant CD5 B cells, in contrast to splenic B cells, are 'partially difference in the proportion or total number of B cell precursors activated' and, furthermore, appear to be arrested in the G 1 in the bone marrow of mutant and wild-type mice (Table 1) .
cell cycle phase (27). Furthermore, there was no difference in the ratio of pre-B:B cells or in the level of expression of B220 or sIgM (Table 1) . Discussion Additionally, the number and phenotype of B cells in the spleen including the marginal zone and follicular B cells were IL-4 or low-dose anti-Ig can promote B cell cycle progression to G 1 ; however, the combination of the two promotes B cell comparable between the mutant and wild-type mice ( Table Table 1 however, most evident in BCR-induced proliferation. Indeed, the B cell proliferative response induced by LPS or CD40 are only minimally affected by loss of cyclin D2. This suggests that the cyclin D2 dependency of BCR-mediated B cell proliferation may be a unique characteristic of antigen receptor signaling rather than a strict role of cyclin D2 in S phase entry in B lymphoid cells. A functional unresponsiveness of the BCR signaling pathway was demonstrated in three experimental systems: (i) low-dose anti-Ig plus IL-4, (ii) optimal concentrations of a monoclonal anti-IgM antibody preparation and (iii) optimal concentrations of a monoclonal anti-IgD antibody preparation. It is important to note, however, that stimulation with a high dose of the polyclonal anti-Ig can induce some proliferation in the mutant B cells. bone marrow is thought to require signaling through the pre-(prepared as described in Methods) (3) CD5 B cells stimulated for BCR which leads to expansion of B cell precursors during 24 h with 1 µg/ml polyclonal F(abЈ) 2 anti-IgM plus 100 U/ml IL-4 or certain developmental stages (28) . Given this, we were sur-(4) unstimulated splenic B cells. Total protein (100 µg) from each sample was used for the Western blotting. Blots were sequentially prised that B cell development proceeded normally in the probed with antibodies against cyclin D2 and D3 as described in mutant mice. Our demonstration that the pre-B cell compart- ment in the mutant mice is comparable to that in the wildtype suggests that pre-BCR-induced proliferation is not dependent on cyclin D2, but may instead require induction cycle progression into S phase. Our results demonstrate that of cyclin D3. Indeed, in our analysis of B cell lines from IL-4 plus anti-Ig, IL-4 alone or anti-Ig alone induce comparable different developmental stages, the D3-expressing B cell lines levels of cyclin D3. However, IL-4 plus anti-Ig but not IL-4
were clustered in the pro-and pre-B cell stages where the alone or anti-Ig alone induce cyclin D2, suggesting that in pre-BCR would be expressed (data not shown). Furthermore, this model system, cyclin D2 is the S phase-promoting factor.
it has been demonstrated that IL-7, a potent growth factor Direct evidence for a non-redundant role for cyclin D2 in G 1 / which promotes the development of precursor B cells, induces S in our system is demonstrated by the dramatic loss of active kinase complexes with cyclin D3 and not D2 (29) . proliferative capacity of B cells from cyclin D2 -/-mice in Additionally, cyclin D3 but not D2 has been detected in response to IL-4 plus low-dose anti-Ig. These results are hematopoietic cells of the fetal liver, a major site of B cell consistent with a specific role for cyclin D2 in the commitment development in the fetus. Together these results suggest that to enter S phase while the ability to enter G 1 may be expansion of B cell precursors during conventional B cell independent of cyclin D2. development is independent of cyclin D2 and may instead require cyclin D3. The role for cyclin D2 in commitment to enter S phase is, the number and proportions of CD5 B cell compartment in the peritoneal cavity. The co-existence of a defect in BCR signaling and CD5 B cell development has previously been References detected in mutant mice in which either natural or genetically
